# Comphya Secures €8M Series A for ED Neurostimulation
_Lausanne-based Comphya SA, a clinical-stage MedTech company, recently closed an oversubscribed Series A financing round, raising €8 million._
**Published:** 2025-07-08
**Source:** https://www.startuphub.ai/ai-news/funding-round/2025/comphya-secures-e8m-series-a-for-ed-neurostimulation
---
Lausanne-based [Comphya SA](https://comphya.com/news/), a clinical-stage MedTech company, recently closed an oversubscribed Series A financing round, raising €8 million. This funding includes the conversion of existing convertible loans. Comphya develops CaverSTIM, an innovative implantable neurostimulation therapy for erectile dysfunction (ED) unresponsive to medication.

Comphya, a prominent [Swiss startup](https://www.startuphub.ai/ai-news/startup-news/2025/landmark-swiss-deep-tech-report-2025-spotlights-switzerlands-rise-as-a-global-leader-in-deep-tech-driving-100b-in-startup-value/), offers CaverSTIM as the first implantable device designed to restore erectile function by activating cavernous nerves. This represents a significant advancement in neurostimulation technology. Existing treatments, such as intrapenile injections or penile implants, often present painful and problematic options for patients. Comphya aims to provide a physiological and improved quality of life solution.

## Advancing Clinical Trials and Market Entry

Proceeds from the Series A round will significantly advance Comphya's clinical development. The company will launch and execute a U.S. pilot study, with the first site activated at Johns Hopkins following FDA Investigational Device Exemption (IDE) approval in January 2025. Furthermore, Comphya plans preparations for a pivotal U.S. clinical trial scheduled for 2026. This funding also expands Comphya’s ongoing clinical trial in Australia, recruiting additional patients.

Encouraging clinical results emerged from the company’s first-in-human study in Australia. Patients undergoing robotic-assisted prostatectomy maintained good erectile function postoperatively without adjunctive therapies. These early outcomes highlight CaverSTIM's potential to address a significant gap in post-prostatectomy care. Pim van Wesel assumed the CEO role in May 2025, guiding the company's clinical growth and strategic execution.
---
Original analysis from [startuphub.ai](https://www.startuphub.ai), the #1 AI startup directory.